Personalised approaches to reduce risks from Adverse Drug Reactions due to administration of multiple medications

Personalised approaches to reduce risks from Adverse Drug Reactions due to administration of multiple medications targets consortia of at least three independent partners from EU Member States or associated countries and supports innovative research in the health sector. With a total budget of €38 million (€8–10 million per project) and a 100% funding rate, the Horizon Europe fund supports research and innovation initiatives. The project start is scheduled for 10 February 2027, with the application deadline on 13 April 2027 (5:00 PM Brussels time). The goal is the development and validation of personalized medicine approaches, including technologies for integrating pharmacogenomics, decision support systems based on electronic health data, as well as biomarker-driven strategies. The focus is on predicting, preventing, and reducing adverse drug reactions in polypharmacy to achieve efficiency gains in health and social systems.

The funding is relevant for patients of all ages, especially multimorbid and elderly patients, as well as healthcare institutions and professionals seeking to improve the safe and effective management of multiple therapies. Eligible costs include personnel expenses, material costs, and subcontractor services, while commercial mass production and retrospective costs are excluded. Evaluation is based on the criteria of excellence, expected impact, and quality and efficiency of implementation. Required application documents include the application form, a financial plan, and an ethics statement. Furthermore, ethical requirements and data protection regulations must be observed. Consortia benefit from international networking, strengthen their innovation capacity, and contribute to evidence-based revisions of guidelines as well as clinical and regulatory frameworks for drug management in polypharmacy.